Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 4/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.47 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5418500 | 0.93 | EGFR (0.48) | EGFRKITERBB2 | |
| SCHEMBL4766613 | 0.92 | EGFR (0.58) | EGFRKITERBB2ERBB4JAK3 | |
| SCHEMBL4769443 | 0.92 | EGFR (0.54) | EGFRKITERBB2ERBB4JAK3 | |
| SCHEMBL4764654 | 0.92 | EGFR (0.51) | EGFRKITERBB2ERBB4 | |
| SCHEMBL4764123 | 0.92 | EGFR (0.52) | EGFRKITERBB2ERBB4JAK3 | |
| SCHEMBL4763823 | 0.92 | EGFR (0.49) | EGFRHPGDERBB2ERBB4JAK3 | |
| SCHEMBL4764461 | 0.87 | EGFR (0.52) | EGFRKITERBB2 | |
| SCHEMBL4764459 | 0.87 | EGFR (0.59) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL4769176 | 0.86 | EGFR (0.58) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL4769248 | 0.84 | EGFR (0.56) | EGFRERBB2ERBB4JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1416935-B1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-03-12 | — | — | EP | claimed |
| US-7244729-B2 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2007-07-17 | — | — | US | claimed |
| US-20040248911-A1 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | BOLD GUIDO (CH) | 2004-12-09 | — | — | US | claimed |
| US-20040242600-A1 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | claimed |
| EP-1416935-B1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248911-A1 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | DPYD, DHPS, TYMP | EGFR 3391/4885HPGD 25/4885KIT 1664/4885 |
| US-20040242600-A1 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | DPYD, TYMP, TYMS | EGFR 2694/4885HPGD 164/4885KIT 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.